Literature DB >> 4036938

Role of delayed indium-111 labeled leukocyte scan in the management of Crohn's disease.

G D Slaton, F Navab, C M Boyd, W C Diner, E C Texter.   

Abstract

Comparison of nine patients with Crohn's disease who had a positive delayed (24 hr) 111indium leukocyte scan and 10 patients with negative scan showed no significant difference between the two groups for the Crohn's disease activity index, sedimentation rate, survival, complications, number of days in hospital, outpatient visits, or readmissions. Despite the apparent lack of statistical significance in Crohn's disease activity index, the scan was positive in nine of 16 patients with a Crohn's disease activity index more than 150, and none of three patients with Crohn's disease activity index less than 150. In the patients studied, there were no false-positive leukocyte scans. In nine of 10 patients with ileocolonic disease, scanning results correctly predicted the proper management. Six patients with positive scan and enteroclysis responded to medical treatment. Four patients had positive enteroclysis and negative scan; of these, three had radiographic features of chronic ileal stricture which was confirmed at operation. The results suggest that a negative delayed indium-111 leukocyte scan may be useful in diagnosis of chronic fibrotic ileal stricture.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4036938

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

1.  Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of X-ray-demonstrated lesions of Crohn's disease.

Authors:  C Brignola; C Belloli; P Iannone; G De Simone; C Corbelli; M Levorato; V Arienti; L Boriani; P Gionchetti; A Belluzzi
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

2.  Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

Authors:  M H Giaffer
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.